

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

<p>BSE Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
<p>Date: August 5, 2017</p>	
<p>Re.: Press Release</p>	

Dear Sir / Madam,

We enclose herewith a copy of press release dated August 5, 2017 titled "Zydus receives final approval from the USFDA for Memantine Hydrochloride Extended-Release Capsules."

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus receives final approval from the USFDA for Memantine Hydrochloride Extended-Release Capsules

Ahmedabad, 5 August 2017

Zydus Cadila has received the final approval from the USFDA to market Memantine Hydrochloride Extended-Release Capsules in strengths of 7 mg, 14 mg, 21 mg, and 28 mg. The drug is used in the treatment of moderate to severe dementia of the Alzheimer's type and will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The sales of Memantine Hydrochloride Extended-Release Capsules is estimated at \$1.1 billion. *Source: IMS Health, IMS National Sales Perspective Audit, MAT June 2017, extracted August 2017.*

The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
